Meropenem
Drug
Shionogi Inc
Total Payments
$23,653
Transactions
34
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $4,525 | 8 | 0 |
| 2018 | $11,724 | 22 | 0 |
| 2017 | $7,404 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $23,653 | 34 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Clinical Study of S-649266 for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens APEKS-NP | Shionogi Inc | $23,653 | 0 |
Top Doctors Receiving Payments for Meropenem
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Deland, FL | $23,653 | 34 |
Ad
Manufacturing Companies
- Shionogi Inc $23,653
Product Information
- Type Drug
- Total Payments $23,653
- Total Doctors 0
- Transactions 34
About Meropenem
Meropenem is a drug associated with $23,653 in payments to 0 healthcare providers, recorded across 34 transactions in the CMS Open Payments database. The primary manufacturer is Shionogi Inc.
Payment data is available from 2017 to 2019. In 2019, $4,525 was paid across 8 transactions to 0 doctors.
The most common payment nature for Meropenem is "Unspecified" ($23,653, 100.0% of total).
Meropenem is associated with 1 research study, including "Clinical Study of S-649266 for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens APEKS-NP" ($23,653).